Skip to main content

Table 1 Baseline characteristics

From: INvestigation on Routine Follow-up in CONgestive HearT FAilure Patients with Remotely Monitored Implanted Cardioverter Defibrillators SysTems (InContact)

 

Telemetry

Personal contact

p-value (telemetry vs. personal contact)

p-value (telemetry vs. remote + phone vs. visit)

 

(N = 102)

n (%) / mean ± SD

All

(N = 108)

n (%) / mean ± SD

Remote + phone

(N = 53)

n (%) / mean ± SD

Visit

(N = 55)

n (%) / mean ± SD

Age (years)

62.5 ± 12.2

65.1 ± 10.1

64.7 ± 9.1

65.4 ± 11.1

0.192

0.312

Female (%)

17 (16.7)

16 (14.8)

7 (13.2)

9 (16.4)

0.712

0.844

Disease parameters

 LVEF (%)

28.2 ± 7.1

28.3 ± 8.9

29.7 ± 10.8

26.9 ± 6.5

0.368

0.562

 NYHA class (mean ± SD)

2.4 ± 0.6

2.3 ± 0.7

2.3 ± 0.7

2.3 ± 0.7

0.524

0.804

 NYHA class (median)

2 (range 1–3)

2 (range 1–3)

2 (range 1–3)

2 (range 1–3)

  

  NYHA I

7.8

12.0

13.2

10.9

  

  NYHA II

48.0

46.3

43.4

49.1

  

  NYHA III

44.1

41.7

43.4

40.0

  

 Cardiac disease type

    

0.834

0.357

  None (%)

0 (0.0)

1 (0.9)

1 (1.9)

0 (0.0)

  

  Ischemic (%)

58 (56.9)

66 (61.1)

30 (56.6)

36 (65.5)

  

  Non-ischemic (%)

41 (40.2)

38 (35.2)

19 (35.8)

19 (34.5)

  

  Other (%)

3 (2.9)

3 (2.8)

3 (5.7)

0 (0.0)

  

 ICD indication

    

0.861

0.508

  Primary prevention

86 (84.3)

92 (85.2)

43 (81.1)

49 (89.1)

  

  Secondary prevention

16 (15.7)

16 (14.8)

10 (18.9)

6 (10.9)

  

Cardiac medication

 None

5 (4.9)

9 (8.3)

4 (7.5)

5 (9.1)

0.319

0.578

 Class 2 (beta-blockers)

96 (94.1)

99 (91.7)

49 (92.5)

50 (90.9)

0.491

0.751

 Class 4

1 (1.0)

1 (0.9)

1 (1.9)

0 (0.0)

1.0

0.744

 Amiodarone

12 (11.8)

12 (11.1)

5 (9.5)

7 (12.7)

0.882

0.856

Cardiac medication

 Diuretics

87 (85.3)

89 (82.4)

43 (81.1)

46 (83.6)

0.570

0.800

 ACE inhibitors

81 (79.4)

86 (79.6)

38 (71.7)

48 (87.3)

0.969

0.134

 ARB

18 (17.6)

16 (14.8)

10 (18.9)

6 (10.9)

0.578

0.456

 Spironolactone

54 (53.5) a

61 (56.5)

28 (52.8)

33 (60.0)

0.661

0.686

Device type

    

0.320

0.313

 ICD Single Chamber

57 (55.9)

51 (47.2)

27 (50.9)

24 (43.6)

  

 ICD Dual Chamber

13 (12.7)

21 (19.4)

12 (22.6)

9 (16.4)

  

 CRT-D

32 (31.4)

36 (33.3)

14 (26.4)

22 (40.0)

  

DF-4 connector

73 (71.6)

77 (71.3)

36 (67.9)

41 (74.5)

0.965

0.748

MLHFQ score PHD

33.6 ± 22.0

33.3 ± 22.0

33.7 ± 24.7

33.0 ± 19.3

0.861

0.976

MLHFQ score at 1 M

24.0 ± 20.3

21.8 ± 19.3

22.8 ± 23.7

20.9 ± 14.2

0.543

0.631

  1. LVEF left ventricular ejection fraction, NYHA New York Heart Association, ICD implantable cardioverter-defibrillator, ACE angiotensin-converting enzyme, ARB angiotensin II receptor blockers, CRT-D cardiac resynchronization therapy implantable cardioverter-defibrillator, MLHFQ Minnesota Living with Heart Failure Questionnaire, PHD pre-hospital discharge, 1 M 1 month
  2. a Data was missing for 1 patient